BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours (NCT04421820)
A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Who can join: Review the eligibility criteria below.
Location: University of California, Los Angeles — Santa Monica, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- University of California, Los Angeles — Santa Monica, California
- Moffitt Cancer Center — Tampa, Florida
- Cross Cancer Institue — Edmonton, Alberta
- Juravinski Cancer Centre — Hamilton, Ontario
- The Ottawa Hospital Cancer Centre — Ottawa, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Jewish General Hospital — Montreal, Quebec
- McGill University Health Centre Glen Site — Montreal, Quebec
- Universitatsklinikum Bonn — Bonn,
- University Hospital of Ulm — Ulm,
- Mater Miserecordiae University Hospital — Dublin,
- St. James Hospital — Dublin,
- St. Vincent's University Hospital — Dublin,
- Fondazione IRCCS "Istituto Nazionale dei Tumori — Milan,
- AOU L. Vanvitelli — Naples,
- Azienda Ospedaliero Universitaria Pisana — Pisa,
- National Cancer Center — Goyang,
- Kangbuk Samsung Hospital — Seoul,
- Samsung Medical Center — Seoul,
- Seoul National University Hospital — Seoul,
- Severance Hospital - Yonsei University — Seoul,
- Vall Hebron Institute of Oncology (VHIO) — Barcelona,
- Early Phase Unit FJD START Madrid — Madrid,
- Hospital 12 de Octubre — Madrid,
📞 Contact the Study Coordinator
Phone: (604) 262-9899
Email: clinical@bold-therapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer
- Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes — Los Angeles, California
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Duarte, California
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) — Houston, Texas
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver — Basking Ridge, New Jersey
- The PRIME-CRC Trial to Promote CRC Screening in Rural Communities — Bastrop, Louisiana
- Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer — Concord, California
Explore by condition: All Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.